NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Partners with Illumina to Expand Genomic Testing in Breast Cancer Care
Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing, to bring improved insights to patients with breast cancer globally IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ January 10, 2022 โ Agendia, Read More
Agendia Appoints Suja Chandrasekaran and Scott Mendel to Board of Directors, Strengthening Advisory Group to Support Company Momentum
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ January 6, 2022 โ Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced the appointment of healthcare industry veterans Suja Chandrasekaran, MS Read More
Agendia Spotlight Poster at SABCS 2021 Confirms Utility of BluePrint as Biomarker Subtyping Test to Guide Neoadjuvant Chemotherapy Decisions
Additional research from the real-world FLEX Registry focuses on age effect and lymph node status for patients with breast cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 10, 2021 โ Agendia, Inc., a world Read More
Analysis Presented at SABCS 2021 Confirms MammaPrint and BluePrint Predict Outcomes Following Neoadjuvant Chemotherapy
Data signal importance of serial genomic testing in order to appropriately adjust breast cancer treatment plans IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 9, 2021 โ Agendia, Inc., a world leader in precision oncology Read More
Agendia Presents Data at SABCS 2021 Showing MammaPrint and BluePrint More Robustly Identify Genomic Differences in HR+ HER2- Breast Cancers in Black and White Women Beyond Clinical Factors
ER+ tumors reclassified by BluePrint as Basal-type occur at a higher frequency in Black women compared to White women Understanding tumor biological differences via MammaPrint and BluePrint and will drive better, more personalized care ย Read More
Agendiaโs MammaPrint Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial
MammaPrint was the only test to predict significant 36% and 52% reductions in DFS and BCFI events, respectively, for patients treated with extended endocrine therapy MammaPrint testing for endocrine management decisions will be available in Read More
Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers
Oral presentation at ASCO 2021 highlights long term data with higher than 99% 8-year breast cancer specific survival for patients with MammaPrint Ultra Low Risk status regardless of clinical risk June 05, 2021 08:00 AM Read More
